Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2010 Aug;29(8):721-7.
doi: 10.1097/INF.0b013e3181e74a2f.

Birth defects among children born to human immunodeficiency virus-infected women: pediatric AIDS clinical trials protocols 219 and 219C

Susan B Brogly  1 , Mark J Abzug, D Heather Watts, Coleen K Cunningham, Paige L Williams, James Oleske, Daniel Conway, Rhoda S Sperling, Hans Spiegel, Russell B Van Dyke
Affiliations
Clinical Trial

Birth defects among children born to human immunodeficiency virus-infected women: pediatric AIDS clinical trials protocols 219 and 219C

Susan B Brogly et al. Pediatr Infect Dis J. 2010 Aug.

Abstract

Background: Some studies have detected associations between in utero antiretroviral therapy (ARV) exposure and birth defects but evidence is inconclusive.

Methods: A total of 2202 human immunodeficiency virus (HIV)-exposed children enrolled in the Pediatric AIDS Clinical Trials Group 219 and 219 C protocols before 1 year of age were included. Birth defects were classified using the Metropolitan Atlanta Congenital Defects Program coding. Logistic regression models were used to evaluate associations between first trimester in utero ARV exposure and birth defects.

Results: A total of 117 live-born children had birth defects for a prevalence of 5.3% (95% confidence interval [CI]: 4.4, 6.3). Prevalence did not differ by HIV infection status or overall ARV exposure; rates were 4.8% (95% CI: 3.7, 6.1) and 5.8% (95% CI: 4.2, 7.8) in children without and with first trimester ARV exposure, respectively. The defect rate was higher among children with first trimester efavirenz exposure (5/32, 15.6%) versus children without first trimester efavirenz exposure (adjusted odds ratio [aOR] = 4.31 [95% CI: 1.56, 11.86]). Protective effects of first trimester zidovudine exposure on musculoskeletal defects were detected (aOR = 0.24 [95% CI: 0.08, 0.69]), while a higher risk of heart defects was found (aOR = 2.04 [95% CI: 1.03, 4.05]).

Conclusions: The prevalence of birth defects was higher in this cohort of HIV-exposed children than in other pediatric cohorts. There was no association with overall ARV exposure, but there were some associations with specific agents, including efavirenz. Additional studies are needed to rule out confounding and to evaluate newer ARV agents.

PubMed Disclaimer

References

    1. Perinatal HIV Guidelines Working Group. Public Health Services Task Force. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. 2009. http://www.aidsinfo.nih.gov.ezp-prod1.hul.harvard.edu/guidelines. - PubMed
    1. Venhoff N, Walker U. Mitochondrial disease in the offspring as a result of antiretroviral therapy. Expert Opinion on Drug Safety. 2006;5(3):373–381. - PubMed
    1. Fundaro C, Genovese O, Rendeli C, et al. Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS. 2002;16(2):299–300. - PubMed
    1. De Santis M, Carducci B, De Santis L, et al. Periconceptional exposure to efavirenz and neural tube defects. Archives of Internal Medicine. 2002;162(3):355. - PubMed
    1. Saitoh A, Hull A, Franklin P, et al. Myelomeningocele in an infant with intrauterine exposure to efavirenz. Journal of Perinatology. 2005;25(8):555–556. - PubMed

Publication types

MeSH terms